Halozyme Therapeutics Company Profile (NASDAQ:HALO)

Analyst Ratings

Consensus Ratings for Halozyme Therapeutics (NASDAQ:HALO) (?)
Ratings Breakdown: 1 Sell Rating(s), 6 Buy Rating(s)
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $15.63 (59.93% upside)

Analysts' Ratings History for Halozyme Therapeutics (NASDAQ:HALO)
Show:
DateFirmActionRatingPrice TargetActions
6/23/2016Piper Jaffray Cos.Reiterated RatingOverweight$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016Canaccord GenuityReiterated RatingBuy$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Jefferies GroupReiterated RatingSell$6.75View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$22.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2016Barclays PLCLower Price TargetOverweight$27.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/18/2015Citigroup Inc.Initiated CoverageBuy$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/22/2015JPMorgan Chase & Co.Boost Price TargetOverweight$20.00 -> $25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2015MLV & Co.Reiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/20/2015BMO Capital MarketsSet Price TargetBuy$26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for Halozyme Therapeutics (NASDAQ:HALO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/9/2016Q116($0.20)($0.16)$29.65 million$42.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q415($0.08)$0.03$37.06 million$52.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.16)($0.19)$24.01 million$20.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.09)$0.02$24.84 million$43.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.13)($0.12)$19.40 million$18.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/2/2015Q414($0.07)($0.04)$25.60 million$30.38 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.14)($0.16)$16.50 million$14.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q214($0.14)($0.13)$13.71 million$18.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q114($0.14)($0.22)$13.37 million$12.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q413($0.17)($0.19)$21.80 million$12.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2013Q313($0.15)($0.17)$14.62 million$16.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2013Q2 2013($0.13)($0.13)$11.29 million$14.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2013Q1 2013($0.15)($0.17)$7.05 million$11.83 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2013Q4 2012($0.16)($0.04)$7.32 million$21.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2012Q312($0.13)($0.18)$6.09 million$5.33 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2012($0.15)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2012($0.11)$0.14ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2012($0.16)($0.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2011($0.03)$0.05ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Halozyme Therapeutics (NASDAQ:HALO)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.20)($0.17)($0.19)
Q2 20161($0.28)($0.28)($0.28)
Q3 20161($0.28)($0.28)($0.28)
Q4 20161($0.29)($0.29)($0.29)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Halozyme Therapeutics (NASDAQ:HALO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Halozyme Therapeutics (NASDAQ:HALO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
8/20/2015Laurie StelzerCFOBuy10,000$17.24$172,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015Kenneth J KelleyDirectorSell20,000$21.00$420,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2014David A RamsayCFOBuy25,000$8.90$222,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2014Helen TorleyCEOBuy50,000$8.92$446,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2014John Stuart PattonDirectorSell75,000$9.96$747,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2014Robert EnglerDirectorSell126,700$7.56$957,852.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013John Stuart PattonDirectorSell75,000$9.13$684,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2013H. Michael ShepardVPSell10,000$7.11$71,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2013Kathryn FalbergDirectorBuy100,000$6.82$682,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/29/2012Robert EnglerDirectorBuy15,000$5.57$83,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/14/2012James P ShafferVPBuy20,000$5.22$104,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2012Kathryn E FalbergDirectorBuy50,000$5.21$260,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2012Kenneth J KelleyDirectorBuy20,000$5.70$114,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2012Gregory Ian FrostCEOBuy2,000$5.50$11,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Halozyme Therapeutics (NASDAQ:HALO)
DateHeadline
07/28/16 03:11 PMAlpha 1-Antitrypsin Deficiency Treatment Market: Competitive Overview
07/27/16 04:37 PMHalozyme Therapeutics, Inc. (NASDAQ:HALO) Earns Consensus ... - Review Fortune
07/27/16 07:07 AMHalozyme Therapeutics, Inc. (NASDAQ:HALO) at $9.24: How much higher it can go - Review Fortune
07/27/16 07:07 AMBRIEF-Halozyme Therapeutics says Eisai and Halozyme initiate Phase 1b/2 clinical trial - Reuters
07/27/16 07:07 AMAnalysts Suggestion Alert: Express Scripts Holding Company (NASDAQ:ESRX) , Halozyme Therapeutics, Inc ... - Street Updates
07/26/16 04:34 PMBlazing Stocks Calls Bulls- Tobira Therapeutics (NASDAQ:TBRA), Halozyme Therapeutics (NASDAQ:HALO), Alnylam ... - Seneca Globe
07/26/16 04:34 PMStock Update (NASDAQ:HALO): Eisai And Halozyme Therapeutics, Inc. Initiate Phase 1b/2 Clinical Trial With First ... - Smarter Analyst
07/26/16 08:18 AMEisai And Halozyme Initiate Phase 1b/2 Clinical Trial With First Patient Dosing Of Eribulin In Combination With PEGPH20 - [at noodls] - SAN DIEGO, July 26, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that Eisai Inc. has dosed the first patient in a collaborative phase 1b/2 clinical trial to assess whether ...
07/25/16 04:25 PMHalozyme Therapeutics (HALO) Resumes Patient Enrollment, Dosing in PEGPH20 Trial
07/25/16 08:58 AM2 Biotech Stocks News And Price Trends: Halozyme Therapeutics, Inc. (NASDAQ:HALO), Juno Therapeutics Inc ... - The Voice Registrar
07/25/16 08:18 AMHalozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Trial With KEYTRUDA - [at noodls] - SAN DIEGO, July 25, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has resumed the enrollment and dosing of patients in its ongoing Phase 1b trial evaluating its ...
07/24/16 08:46 AMAnalyst Views That Are Worth Watching: Halozyme Therapeutics, Inc. (NASDAQ:HALO), NCI Building Systems Inc ... - Review Fortune
07/22/16 07:18 AMA Reversal for Halozyme Therapeutics, Inc. Is Not Near. The Stock Rises Again - Consumer Eagle
07/22/16 07:18 AMActive biotech company shares in the news: Halozyme Therapeutics (NASDAQ:HALO), BioMarin Pharmaceutical ... - The Voice Registrar
07/22/16 07:18 AMPrice Target Review: Halozyme Therapeutics, Inc. (NASDAQ:HALO) - News Oracle
07/22/16 07:18 AMLatest Halozyme Therapeutics, Inc. (NASDAQ:HALO) Target Price Suggests Stock Is Worth $14.54/Share - Review Fortune
07/21/16 07:14 AMHalozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US : July 21, 2016 -
07/20/16 08:40 PMIncreased Stock Volatility Watch: Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Engelwood Daily
07/20/16 08:40 PMHalozyme Therapeutics Inc. (HALO) Jumps 6.66% on July 20 - Equities.com
07/20/16 02:18 PMHalozyme Therapeutics, Inc.'s Trend Up, Especially After Today's Strong Session - Consumer Eagle
07/20/16 11:31 AMETF’s with exposure to Halozyme Therapeutics, Inc. : July 20, 2016 -
07/20/16 07:15 AMEquity Roundup: Stock Performance Focus on Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Press Telegraph
07/19/16 10:30 AMEarnings Focus and Crowd Sourced Sentiment Review for Halozyme Therapeutics, Inc. (NASDAQ:HALO) - TGP
07/19/16 10:30 AMHalozyme Therapeutics Inc versus MiMedx Group Inc Head to Head Compare - CML News
07/19/16 10:30 AMIntraday Active Biotech Stocks News: Halozyme Therapeutics, Inc. (NASDAQ:HALO), Amicus Therapeutics, Inc ... - The Voice Registrar
07/18/16 04:34 PMShare Performance Summary for: Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Press Telegraph
07/18/16 04:34 PMTrending Analyst Recommended Stock: Halozyme Therapeutics, Inc. (NASDAQ:HALO) - News Oracle
07/18/16 09:34 AMColon Cancer Pipeline Market 2016 Review Report Covering Therapeutics Development
07/16/16 04:08 PMShares Experiencing a Downtrend: Halozyme Therapeutics, Inc. (NASDAQ:HALO) - TGP
07/15/16 07:31 AMStocks in Review: Halozyme Therapeutics, Inc. (HALO), CVR Refining, LP (CVRR), TherapeuticsMD, Inc. (TXMD) - iStreetWire
07/15/16 07:31 AMHalozyme Therapeutics (HALO): Price Target and June Short Interest Disclosure - Trade Calls
07/15/16 07:31 AMHalozyme Therapeutics Inc. (HALO) Drops 6.15% on July 13 - Equities.com
07/14/16 04:33 PMBiotech Stocks To Put On Your Watch List: ImmunoGen, Inc. (NASDAQ:IMGN), Halozyme Therapeutics, Inc. (NASDAQ ... - The Voice Registrar
07/14/16 04:33 PMEnanta Pharmaceuticals Inc versus Halozyme Therapeutics Inc Head to Head Compare - CML News
07/14/16 07:52 AMAnalyst Target and Average Rating Watch: Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Press Telegraph
07/13/16 04:46 PMRemarkable Stocks News Analysis: Kellogg Company, (NYSE:K), Halozyme Therapeutics, (NASDAQ:HALO) - Money News (press release)
07/13/16 07:14 AMHow Analysts Feel About Halozyme Therapeutics, Inc. (NASDAQ:HALO)? - Press Telegraph
07/13/16 07:14 AMOption Market: Halozyme Therapeutics Inc Risk Hits An Elevated Level - CML News
07/13/16 07:14 AMHalozyme To Host Second Quarter 2016 Financial Results Conference Call - PR Newswire (press release)
07/13/16 07:14 AMShort Term Rating on Halozyme Therapeutics (HALO) - TheFounders Daily
07/11/16 03:53 PMHalozyme To Host Second Quarter 2016 Financial Results Conference Call - [at noodls] - SAN DIEGO, July 11, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2016 on Tuesday, August 9, 2016 at 4:30 p.m. ...
07/10/16 08:47 AMNext Weeks Broker Price Targets For Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Fiscal Standard
07/08/16 07:11 AMHot Stock under Consideration: Halozyme Therapeutics, Inc. (NASDAQ:HALO) - News Oracle
07/08/16 07:11 AMBroker Outlook For Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Fiscal Standard
07/07/16 07:12 AMHalozyme Therapeutics Inc. (HALO) Drops 6.24% on July 05 - Equities.com
07/07/16 06:27 AMThese 5 Stocks Under $10 Are Set to Soar -
07/06/16 09:01 AMStock Tracking Down This Month; Investor Alert on Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Engelwood Daily
07/06/16 09:01 AMHalozyme Therapeutics Inc. (HALO) Jumps 5.79% on July 04 - Equities.com
07/05/16 09:01 AMWere Analysts Bearish Halozyme Therapeutics, Inc. (NASDAQ:HALO) This Week? - Engelwood Daily
07/04/16 03:59 PMShare Performance Recap for: Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Press Telegraph

Social

About Halozyme Therapeutics

Halozyme Therapeutics logoHalozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant. Its development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: HALO
  • CUSIP: 40637H10
Key Metrics:
  • Previous Close: $9.77
  • 50 Day Moving Average: $8.90
  • 200 Day Moving Average: $9.35
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $1.25B
  • Beta: 2.05
  • Current Year EPS Consensus Estimate: $-1.03 EPS
  • Next Year EPS Consensus Estimate: $-0.77 EPS
Additional Links:
Halozyme Therapeutics (NASDAQ:HALO) Chart for Thursday, July, 28, 2016